Bulletin of Russian State Medical University, published by the esteemed PIROGOV RUSSIAN NATL RESEARCH MEDICAL UNIV, serves as a crucial platform for advancing the field of medicine, particularly in the context of Russian healthcare advancements. With an ISSN of 2500-1094 and an E-ISSN of 2542-1204, this journal has emerged as a valuable resource for researchers, professionals, and students alike, enriching the academic landscape since its inception. Although categorized in the Q4 quartile for Medicine (miscellaneous) and currently ranked #385 out of 636 in the Scopus database, its ongoing commitment to disseminating vital research and clinical studies positions it as a respected, though evolving, contributor to the global medical community. Operating without an open-access model, it ensures the dissemination of quality-controlled scientific information while maintaining professional integrity. Spanning the intersecting domains of healthcare practices and medical science, the journal strives to provide insights and promote discussions that address contemporary challenges in the field, making it an essential read for anyone looking to stay at the forefront of medical research and practices in Russia and beyond.

The Journal of Hepatocellular Carcinoma is a pivotal open-access publication dedicated to advancing the field of hepatocellular carcinoma research. Published by DOVE MEDICAL PRESS LTD since 2014, this journal seeks to disseminate high-quality articles that explore innovative treatments, clinical trials, and emerging research in the context of liver cancer. With its ISSN: N/A and E-ISSN: 2253-5969, the journal is optimized for a global audience, ensuring accessibility to a broad spectrum of researchers, healthcare professionals, and students engaged in oncology and hepatology. While its Scopus ranking places it in the lower quartiles of the respective fields, the journal continues to strive for growth and visibility in a rapidly evolving landscape. The Journal of Hepatocellular Carcinoma is an essential resource for anyone seeking to enhance their understanding of liver diseases and contribute to the fight against hepatocellular carcinoma.

The Japanese Journal of Clinical Oncology, published by Oxford University Press, is a pivotal platform for advancing knowledge in the fields of cancer research, oncology, and related medical disciplines. Since its inception in 1971, this journal has contributed significantly to the dissemination of cutting-edge research and clinical practices, featuring a breadth of scholarly articles that cater to the needs of researchers, practitioners, and students alike. With an impact factor reflecting its robust reputation, the journal is ranked in the Q3 category for both Cancer Research and Oncology, and Q2 in Medicine (miscellaneous), and Radiology, Nuclear Medicine and Imaging as of 2023. These rankings, alongside the journal's Scopus rankings, signify its important role in the scientific community and its commitment to fostering innovative research. Although it is not an Open Access journal, the Japanese Journal of Clinical Oncology continues to provide valuable insights and educational resources, making it essential for anyone engaged in the fight against cancer.

Cancer Research and Treatment is a premier academic journal published by the Korean Cancer Association that focuses on advancing scientific knowledge and clinical practices in the fields of cancer research and oncology. With an ISSN of 1598-2998 and an E-ISSN of 2005-9256, the journal showcases cutting-edge research articles, clinical trials, and comprehensive reviews that address the multifaceted challenges in cancer treatment and management. Published in South Korea, this journal has established itself as a critical resource, evidenced by its Q1 rank in Oncology and Q2 rank in Cancer Research, reflecting its influence and stature within the academic community. The impact of research disseminated through Cancer Research and Treatment is underscored by its significant percentile rankings in Scopus, with notable positions in both the pharmaceutical and biological sectors. This journal aims to bridge the gap between laboratory research and clinical application, providing a platform for researchers, healthcare professionals, and students to enhance their understanding of cancer-related innovations and therapeutic strategies. Readers will benefit from rich content that not only discusses the latest advancements but also engages with pressing global health issues related to cancer.

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, published by Elsevier Taiwan, stands as a significant academic resource in the field of medical research, particularly within the miscellaneous categories of medicine. With an impressive impact factor and categorized within the Q2 tier of medical journals, it boasts a commendable position in Scopus rankings—#63 out of 636 in General Medicine, placing it in the 90th percentile. Established initially in 1961 and evolving through its open access format since 2016, this journal fosters the dissemination of innovative research, serving an important role in the global medical community. Located in Taipei, Taiwan, it particularly emphasizes studies relevant to the Taiwanese population while welcoming international contributions, enhancing both local and global health discourse. As a trusted platform for researchers, professionals, and students alike, the journal aims to propel advancements in medical science and practice through high-quality peer-reviewed articles. ISSN: 0929-6646, E-ISSN: 1876-0821.

The Lancet Rheumatology, published by Elsevier, is a premier academic journal dedicated to advancing the understanding of rheumatology and immunological diseases. Launched in 2019, this esteemed publication has quickly become a leading source of research, achieving an impressive Q1 ranking in both the fields of Rheumatology and Immunology as of 2023. With Scopus rankings placing it at #2 out of 73 in Medicine - Rheumatology and #6 out of 233 in Medicine - Immunology and Allergy, the journal serves as an essential platform for disseminating high-quality, peer-reviewed articles that address the latest findings and clinical practices in these domains. The journal, accessible in print and online, is committed to fostering knowledge and collaboration among researchers, healthcare professionals, and students alike, making it an invaluable resource for those seeking to deepen their expertise in rheumatology and its interrelated fields.

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.

Frontiers in Medicine, published by FRONTIERS MEDIA SA, is a distinguished open-access journal that has been at the forefront of medical research since its inception in 2014. With an impressive 2023 Q1 ranking in the field of miscellaneous medicine and a notable Scopus rank of #93 out of 636—placing it in the 85th percentile in the general medicine category—this journal serves as a pivotal resource for academics and practitioners. Hailing from Switzerland, Frontiers in Medicine aims to publish high-quality research that addresses the most pressing issues in the medical field, fostering innovation and collaboration among researchers worldwide. By facilitating open access to comprehensive, peer-reviewed articles, the journal enhances the dissemination of knowledge and encourages interdisciplinary dialogues essential for medical advancement. Whether you're a researcher, a clinician, or a student, this journal is an invaluable tool for staying abreast of the latest developments in medicine.

CHINESE MEDICAL JOURNAL, published by Lippincott Williams & Wilkins, is a distinguished platform within the field of medicine, providing a vital forum for the dissemination of innovative research and clinical findings since its inception in 1946. With its open access model established in 2000, the journal ensures that critical medical advancements and insights are accessible to a global audience, fostering collaboration and continuous learning among researchers, healthcare professionals, and students alike. The journal’s impressive Q1 ranking in Medicine (miscellaneous), alongside its remarkable Scopus rank of #40 out of 636 in General Medicine, underscores its influential presence in the medical community, promoting high-quality research that advances health outcomes. As it converges historical and contemporary research, the CHINESE MEDICAL JOURNAL plays an essential role in bridging academic inquiry with practical medical application, emphasizing its commitment to improving global healthcare through rigorous scholarship and excellence.

Therapeutic Advances in Medical Oncology, an esteemed journal published by SAGE Publications Ltd, serves as a critical platform for disseminating high-quality research pertinent to the field of oncology. Indexed under the ISSN 1758-8340 and E-ISSN 1758-8359, this Open Access journal has made significant strides since its inception in 2009, attaining a commendable rank of #78 out of 404 in the Medicine - Oncology category of Scopus, placing it in the top 20th percentile of journals. With its category quartile of Q1 established in 2023, it underscores the journal’s commitment to advancing therapeutic approaches in oncology, making it an invaluable resource for researchers, clinicians, and students alike. Offering unrestricted access to pioneering studies since 2017, it aligns with the global movement towards open science, fostering collaboration and innovation among professionals striving to improve cancer treatment outcomes. By bridging the gap between research and clinical practice, Therapeutic Advances in Medical Oncology plays a vital role in shaping the future of cancer therapy.